11:39 AM EST - Theralase Technologies Inc. : announced today that it has successfully launched its TLC-3000 multi wavelength laser system capable of activating its patented and patent pending Photo Dynamic Compounds for the destruction of cancer in an preclinical environment. This is the first commercial system on the market capable of effectively activating a 96 well plate of cancer cells with wavelengths in the visible to Near Infrared spectrum using programmable energy levels. Intellectual protection for this system was recently applied for under a pending U.S. patent. Theralase Technologies Inc.
shares V.TLT are trading up $0.02 at $0.34.
